SkinHealth Systems now carries a refreshed fair value estimate of about US$15.67 per share, down from roughly US$19.83, which resets the central price target in the current model. This aligns with recent Street commentary that has clustered around US$10 to US$11 price targets and Hold ratings, reflecting a cautious but not outright negative stance on the stock. As you read on, you will see how these shifts fit into the broader analyst narrative and what to watch as the story continues to evolve.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Canaccord, Jefferies and Stifel all carry Hold ratings on SkinHealth Systems, which signals that current valuation is seen as balanced rather than strongly mispriced.
-
Canaccord raised its price target to US$11 from US$1 ahead of quarterly results. This indicates a meaningful reset in its model even while keeping a neutral stance on the shares.
-
Jefferies and Stifel each moved to double digit price targets of US$11 and US$10 after the 1 for 20 reverse split, suggesting that their updated frameworks still allow for the story to play out.
🐻 Bearish Takeaways
-
The consistent use of Hold ratings across TD Cowen, Canaccord, Jefferies and Stifel points to hesitation around SkinHealth Systems execution and growth profile, rather than clear conviction on upside.
-
TD Cowen previously reduced its target to US$0.90 from US$1 after Q2, citing Delivery Systems weakness and softer utilization. This keeps competitive pressure and capital intensity squarely in focus for investors.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 2 risks for SkinHealth Systems. See which could impact your investment.
How This Changes the Fair Value For SkinHealth Systems
-
Fair value for SkinHealth Systems has moved from about US$19.83 to about US$15.67 per share.
-
Revenue growth in the model is about 3.36% in both the prior and updated assumptions.
-
Net profit margin has adjusted from about 7.86% to about 7.88% in the refreshed assumptions.
-
Future P/E has shifted from about 7.77x to about 6.13x in the updated framework.
-
The discount rate remains effectively unchanged at about 12.54% in both models.
Never Miss an Update: Follow The Narrative
Narratives connect SkinHealth Systems' business story with analyst forecasts and a fair value anchor, then update as new information comes through. They help you see how product, regulatory and competitive trends feed into the numbers you are looking at.
Head over to the Simply Wall St Community and follow the Narrative on SkinHealth Systems to stay up to date on:
-
How the heavy reliance on premium Hydrafacial treatments and consumables shapes long term demand risk if consumer trends or spending patterns change.
-
The role of recurring consumables revenue, product launches like new boosters and skincare lines, and an expanding global device base in supporting revenue stability.
-
Regulatory and sustainability pressures, along with competition from large beauty companies and indie brands, that could raise costs or pressure SkinHealth Systems' market share.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SKIN .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
